Experienced in Hodgkin Lymphoma

Dr. Michael L. Haas

Radiation Oncology
Reading Hospital
206 S 6th Ave, 
West Reading, PA 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Hodgkin Lymphoma
Reading Hospital
206 S 6th Ave, 
West Reading, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Haas is a Radiation Oncologist in West Reading, Pennsylvania. Dr. Haas is rated as an Experienced provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Familial Prostate Cancer, Lung Cancer, Pleuropulmonary Blastoma, Vulvar Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Hospital Affiliations
Reading Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

READING HOSPITAL
206 S 6th Ave, West Reading, PA 19611
Other Locations
READING HOSPITAL
420 S 5th Ave, West Reading, PA 19611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
Enrollment Status: Recruiting
Publish Date: September 05, 2025
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Lomustine, Temozolomide
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women With Early Stage Breast Cancer (PBI 3.0)
Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women With Early Stage Breast Cancer (PBI 3.0)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Radiation, Drug
Study Drug: Lapatinib Ditosylate
Study Phase: Phase 2
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
Enrollment Status: Unknown
Publish Date: July 19, 2017
Intervention Type: Drug
Study Drugs: Gemcitabine, Afatinib
Study Phase: Phase 2
View 12 Less Clinical Trials

8 Total Publications

Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203.
Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203.
Journal: JCO oncology advances
Published: October 22, 2024
Similar Doctors
Distinguished in Hodgkin Lymphoma
Dr. John P. Plastaras
Radiation Oncology
Distinguished in Hodgkin Lymphoma
Dr. John P. Plastaras
Radiation Oncology

Penn Radiation Oncology Penn Presbyterian

51 N. 39th Street, Pavilion For Advanced Care, Suite 100, 
Philadelphia, PA 
 (47.4 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Plastaras is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Plastaras is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, T-Cell Lymphoma, Mediastinal Tumor, and Midline Lethal Granuloma. Dr. Plastaras is currently accepting new patients.

Glenn B. Mieszkalski
Distinguished in Hodgkin Lymphoma
Dr. Glenn B. Mieszkalski
Radiation Oncology
Distinguished in Hodgkin Lymphoma
Dr. Glenn B. Mieszkalski
Radiation Oncology

UPMC Hillman Cancer Center At UPMC Memorial

1703 Innovation Drive, Suite 100, 
York, PA 
 (52.9 miles away)
717-801-0742
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Glenn B. Mieszkalski, MD, specializes in radiation oncology and is board-certified in radiation oncology by the American Board of Radiology. He is affiliated with UPMC Hanover, UPMC Carlisle, UPMC Memorial, UPMC Lititz, UPMC Community Osteopathic, UPMC Pinnacle Harrisburg and UPMC West Shore. Dr. Mieszkalski completed his residency and medical degree at Hahnemann University School of Medicine. Dr. Mieszkalski is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Familial Prostate Cancer, and Adenoid Cystic Carcinoma.

Joseph W. Fanelle
Distinguished in Hodgkin Lymphoma
Dr. Joseph W. Fanelle
Radiation Oncology
Distinguished in Hodgkin Lymphoma
Dr. Joseph W. Fanelle
Radiation Oncology

UPMC Hillman Cancer Center At UPMC Memorial

1703 Innovation Drive, Suite 100, 
York, PA 
 (52.9 miles away)
717-801-0742
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Fanelle, MD, specializes in radiation oncology and is board-certified in radiation oncology by the American Board of Radiology. He practices at UPMC Pinnacle Radiation Oncology and is affiliated with UPMC Memorial, UPMC Carlisle, UPMC West Shore, UPMC Community Osteopathic, and UPMC Pinnacle Harrisburg. Dr. Fanelle completed his medical degree at Hahnemann University School of Medicine and residency at Cooper University Hospital. Dr. Fanelle is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Hodgkin Lymphoma, and Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haas's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 30 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile